---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-145242"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:45:14.140512+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines secures up to $2B financing from Royalty Pharma, withdraws cash runway guidance

## Summary
- Received $250M upfront from Royalty Pharma; up to $1.25B total synthetic royalty on daraxonrasib sales.
- Loan facility of up to $750M senior secured term loan (SOFR+5.75%, 3.50% floor), interest-only, matures by 2032.
- Additional tranches tied to daraxonrasib approval milestones; company retains global commercialization control.
- Withdraws prior cash runway end date and 2025 GAAP net loss guidance; expects updated guidance in Q2 2025 earnings.

## SEC filing metadata
- accession: 0001193125-25-145242
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312525145242/0001193125-25-145242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312525145242/d838043d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-145242
- JSON: https://secwatch.observer/filing/0001193125-25-145242.json
- Plain text: https://secwatch.observer/filing/0001193125-25-145242.txt

## Key facts
- Debt Financings
  Revolution Medicines, Inc. incurred debt of $250.0 million with Royalty Pharma Investments 2019 ICAV maturing 15 years after the first commercial sale of RMC-6236 in the United States.
  - Principal: $250.0 million
  - Counterparty: Royalty Pharma Investments 2019 ICAV
  - Maturity: 15 years after the first commercial sale of RMC-6236 in the United States
  - Event: incurrence
  source text: On June 23, 2025 (the “Effective Date”), Revolution Medicines, Inc. (the “Company”) entered into a revenue participation right purchase and sale agreement (the “Royalty Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”). Pursuant to the Royalty Purchase Agreement, in exchange for an upfront payment of $250.0 million, Royalty Pharma purchased from the Company the right to receive tiered revenue payments (the “Royalty Payments”) with respect to worldwide net product sales
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312525145242/0001193125-25-145242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.